Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Inclusion Criteria: * Patients aged ≥ 18 years old. * Patients with any of the following hematologic malignancies for which allo-HCT is indicated, including: * Acute myeloid leukemia (AML) with intermediate or high-risk features in CR1. * Relapsed AML in ≥ CR2. * Acute leukemias of ambiguous lineage in ≥ CR1. * Acute lymphoid leukemia (ALL) in CR1 with clinical, flow cytometric, or molecular features indicating a high risk for relapse, or ALL in ≥ CR2. * CML meeting one of the following criteria: * Failed response to or intolerant to BCR-ABL tyrosine kinase inhibitors (TKIs). * CML with BCR-ABL mutation consistent with poor response to TKIs (e.g., T315I mutation) * CML in accelerated phase or blast crisis with \<10% blasts after therapy, or in second chronic phase. * Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), or MDS/MPN overlap syndromes with least one of the following: * Revised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation. * Life-threatening cytopenias. * Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype. * Therapy related disease or disease evolving from other malignant processes. * Chronic myelomonocytic leukemia (CMML-1 or CMML-2). * Severe aplastic anemia. * Relapsed Hodgkin lymphoma meeting both …